Mindfulness-based stress reduction for inflammatory skin conditions
Evaluation of the Therapeutic Efficacy of a Mindfulness-Based Stress Reduction (MBSR) Program as an Adjuvant Therapy in Patients With Moderate Pruritic Inflammatory Dermatosis (Psoriasis or Atopic Dermatitis)
This study is testing whether mindfulness techniques can help adults with inflammatory skin conditions like psoriasis and eczema feel less itchy and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 18 Days and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT05500794 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of Mindfulness-Based Stress Reduction (MBSR) on patients suffering from inflammatory dermatoses such as psoriasis and atopic dermatitis. It aims to alleviate significant pruritus and improve the overall quality of life by addressing both the physical symptoms and the psychological impact of these conditions. Participants will be assessed based on their pruritus severity and quality of life metrics, with a focus on enhancing coping mechanisms and reducing distress. The study targets adults with moderate symptoms who can communicate in French.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with moderate psoriasis or atopic dermatitis and significant pruritus.
Not a fit: Patients with severe psychiatric disorders or those currently undergoing systemic treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for patients with inflammatory skin conditions by reducing itching and psychological distress.
How similar studies have performed: Previous studies have shown promising results for mindfulness interventions in managing chronic conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 years old or older * With health insurance coverage * Significant pruritus defined by a Visual Analogical Scale (VAS) pruritus ≥ 4 * Patient with plaque psoriasis * Without joint involvement * Mild to moderate severity (PASI\>10) * DLQI \> 10 OR Patient with atopic dermatitis: * Mild to moderate severity (SCORAD\>10) * DLQI \> 10 * Diagnosis according to Hanifin and Raijka criteria * Patient in a stable psychological state * French langage spoken Exclusion Criteria : * Current systemic treatment or treatment discontinued within the last month * Psychiatric illnesses diagnosed according to the DSM-5 or ICD-10 international criteria of psychotic disorder, severe anxiety disorder, depressive disorder with a current depressive episode of severe intensity, bipolar disorder with a current depressive or manic episode * Taking psychotropic or neuroleptic treatments * Participation in another interventional research study or being in the exclusion period at the end of a previous study, if applicable * Patient under AME
Where this trial is running
Paris
- Hôpital Saint-Louis — Paris, France (Recruiting)
Study contacts
- Study coordinator: Charles CASSIUS, Dr
- Email: charles.cassius@aphp.fr
- Phone: +331.42.38.50.49
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.